Generic competition to Prograf (tacrolimus) in the US continued to weigh on Astellas in the fiscal first quarter ended 30 June, although contributions from US acquisition OSI and newer products offset the decline.
Generic competition to Prograf (tacrolimus) in the US continued to weigh on Astellas in the fiscal first quarter ended 30 June, although contributions from US acquisition OSI and newer products offset the decline.
Sales of the immunosuppressant in the Americas slumped by 21% to $97 million, below the firm's internal forecast, with generics...
Create an account to read this article
Already a subscriber?
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
